The Great Peptide Divide

GLP-1 receptor agonists have largely reshaped the conversation about weight management and metabolic health. They have also (re)-introduced millions of consumers to peptides, a term familiar to many people that is now widely promoted by wellness influencers and longevity clinics.

According to Google Trends, U.S. searches for “GLP-1” increased roughly 180% over the past year, while searches for “peptides” climbed 250%.

For the dietary supplement industry, this heightened interest presents both opportunity and risk.

A fast-moving gray market of online retailers, med spas, and some rogue compounding pharmacies has been marketing unapproved peptide drugs for everything from obesity and muscle growth/recovery to insomnia, wound healing, opioid withdrawal, and anti-aging/longevity. However, these products have not undergone rigorous human clinical trials to evaluate their safety or efficacy, and quality can be questionable.

Subscribe to our newsletter to stay up to date with all our content.

Growing public interest has drawn regulators into the mix. Health and Human Services Secretary (HHS) Robert F. Kennedy, Jr. has advocated for loosening restrictions on certain peptide therapies, though many career scientists appear skeptical.

FDA’s Pharmacy Compounding Advisory Committee was scheduled to meet July 23-24, to evaluate seven peptides, including BPC-157, for potential addition to the Section 503A Bulk Drug Substances List, which governs what compounding pharmacies can legally prepare for individual patients.

The peptides had been on FDA’s “do-not-compound” Category 2 list since 2023 but were moved off it in April 2026 as part of settling litigation with the compounding industry, putting them in regulatory limbo pending this review.

In briefing documents prepared for the meeting, FDA staff recommended against listing any of the seven, citing a consistent set of problems: poor physical/chemical characterization, insufficient historical compounding use data, lack of evidence of effectiveness, and insufficient safety data.

The committee’s vote will only be advisory, as FDA still must go through formal rulemaking, a process that could take months to years. In the meantime, these peptides remain widely available online, often marketed for “research use only,” outside formal pharmaceutical oversight.

Multiple Meanings

Dietary supplement industry experts have noted that the public has been using the term “peptide” to describe products spanning very different scientific and regulatory categories, including FDA-approved prescription drugs, compounded medications, experimental compounds, and lawful dietary supplement ingredients. (See Table 1.)

Without clearer distinctions, consumer confusion could undermine confidence in legitimate nutritional peptide innovation.

“The first thing we need to do is separate these into different categories because right now people are using the word ‘peptides’ as if it describes one product category,” said Oliver Catlin, president and co-founder of the Banned Substances Control Group (BSCG). “It doesn’t.”

Scientifically, peptides are simply short chains of amino acids, but from a regulatory standpoint, the marketplace is much more complex. The term describes a molecular structure, not a regulatory category.

FDA-approved peptide drugs such as GLP-1 receptor agonists undergo extensive clinical testing and FDA review before reaching patients. Peptide drugs aren’t new. Insulin became the first therapeutic peptide used clinically after its discovery in the early 1920s.

Meanwhile, compounded peptide medications prepared by licensed pharmacies for individual patients under federal and state compounding laws are not FDA-approved drugs, nor are they dietary supplements.

A third category encompasses experimental pharmaceutical peptides, including compounds such as BPC-157 and TB-500, which have gained popularity online despite not being approved as drugs. They are also not lawful dietary supplement ingredients.

Finally, there are nutritional peptides: bioactive compounds derived from food proteins through enzymatic hydrolysis, fermentation, or other manufacturing technologies that may be marketed as dietary ingredients when they comply with the Dietary Supplement Health and Education Act (DSHEA) and applicable statutes.

“There are legitimate dietary supplement ingredient peptides, such as collagen peptides or bioactive peptides derived from food proteins, that are appropriate for dietary supplement use if they comply with DSHEA,” Catlin said. “Then there are pharmaceutical peptides that were developed as drugs.”

The confusion, he added, begins when pharmaceutical peptides are marketed as dietary supplements. “Simply calling something a supplement doesn’t make it one.”

Next-Gen Nutritional Peptides

Although pharmaceutical peptides dominate headlines, experts see growing potential for nutritional peptides derived from food proteins.

Robert Wildman, chief science officer, TCI Biotech, noted that peptides have always been part of human nutrition. “When you make a peptide, you start with a protein,” he said. Enzymatic processes break proteins into shorter amino acid chains that can exhibit biological activity.

Scientists have long studied peptides naturally released from foods such as dairy proteins, while digestion of human breast milk produces dozens of peptides believed to contribute to infant development.

Today, advances in analytical chemistry, precision fermentation, protein characterization, and computational discovery are accelerating the identification of novel bioactive peptides from plants, marine sources, dairy, and microorganisms.

“We’re really at the frontier of this category,” Wildman said.

Unlike pharmaceutical peptide developers that design molecules to target specific receptors, nutritional peptide companies are identifying naturally occurring peptide sequences hidden within food proteins that may support normal physiological functions.

For example, Nuritas is a Dublin-based biotech company dedicated to the clinical validation of bioactive peptides. Using its proprietary Magnifier AI platform, Nuritas analyzes natural protein sources (like fava beans and rice husks) to isolate and test potent, plant-derived peptides. The company’s flagship ingredients include PeptiStrong for muscle health and strength recovery, and PeptiSleep for cortisol reduction and sleep support.

Meanwhile, GELITA is a global manufacturer specializing in bioactive collagen peptides, discovering and developing scientifically supported solutions for sports nutrition, joint mobility, and skin health.

Additionally, Ingredia is a French dairy cooperative that develops patented bioactive milk protein hydrolysates and peptides targeting stress, blood sugar, bone, and cognitive health.

Unlike pharmaceutical peptides designed to treat disease or produce therapeutic effects, nutritional peptides are intended to support normal structure and function and must comply with dietary supplement regulations, including current Good Manufacturing Practices (cGMPs) and New Dietary Ingredient Notification (NDIN) requirements.

Rather than attempting to replicate drug effects, Catlin believes the greatest opportunity lies in developing well-characterized food-derived peptides backed by clinical research and transparent manufacturing.

When Categories Become Blurred

“I get asked about it weekly,” Wildman said about the peptide landscape, noting that questions increasingly come from athletes, practitioners, and consumers curious about compounds such as BPC-157.

Part of the problem, he said, is that consumers often hear the word peptide without understanding that it may refer to entirely different types of products.

“We have peptides on the nutritional side, and then we have peptides in this gray drug-like world that people can order online,” he said. “We need to clearly define the difference between a nutritional peptide and a drug-like peptide or pharmaceutical peptide, and separate the two to minimize confusion.”

Catlin expressed concern that many consumers assume products sold online are manufactured under the same standards that govern dietary supplements.

“The biggest misconception is that if a pharmaceutical peptide is available online it must be legal,” he said.

“DSHEA was instituted to separate drugs and dietary supplements and to allow supplements to hold a special status in our society,” he noted. “Supplements have a defined set of regulations and GMP requirements to protect consumers. The biggest risk for consumers is that they assume unapproved pharmaceutical peptides are subject to the same GMP and quality control regulations that apply to dietary supplements.”

Concerns about experimental peptide products include inconsistent potency, inaccurate labeling, contamination, and uncertain purity. Catlin noted that testing within the peptide marketplace has identified endotoxin contamination in some injectable products, highlighting the importance of ingredient verification and manufacturing controls.

“We have seen countless articles in the past assailing the dietary supplement industry for being unregulated, and they are often associated with the sale of illegal supplement ingredients like prohormones, designer stimulants, or SARMS,” said Catlin. “Now we have an entire unregulated industry being commingled with dietary supplements, and I worry that history will soon repeat itself.”

When illegal drug ingredients are marketed as legitimate supplements, “consumers don’t distinguish between the two, and neither does the media,” he added.

Wildman also emphasized that the dietary supplement industry must distinguish nutritional peptides from pharmaceutical compounds while continuing to educate consumers about what qualifies as a lawful dietary ingredient.

He called for continued collaboration among trade associations, manufacturers, retailers, and regulators to reinforce regulatory compliance and consumer education.

“We need to have a collective voice that says, ‘We’re turning our back on that practice. It is not part of the compliant dietary supplement industry.’”

A View from Compounding Pharmacies

Representatives of the peptide compounding industry argue that discussions surrounding peptides often fail to distinguish licensed pharmacy compounding from experimental products sold through online channels.

Jeff Cohen, co-founder of the American Peptide Association, said compounded medications have long occupied a separate regulatory pathway from FDA-approved drugs.

“‘FDA-approved’ and ‘safe and effective’ are not synonyms,” Cohen said. “Compounded medications have always been ‘not FDA approved’ — that is a legal definition, not a safety metric.”

While acknowledging that quality practices vary considerably across the marketplace, Cohen said consumers should expect transparency regardless of where peptide products originate.

“If a company or provider cannot immediately produce a verified Certificate of Analysis from an independent lab showing purity, potency, and the absence of contaminants, walk away,” he said. “Legitimate, high-integrity operators are never defensive about their quality standards.”

Although Catlin and Cohen differ on aspects of the regulatory landscape, both agree that quality systems, ingredient verification, and transparency are essential as consumer demand continues to grow.

What to Watch

Despite today’s regulatory confusion, many industry experts agree that nutritional peptides represent one of the most promising areas of future ingredient innovation.

Advances in ingredient discovery, precision fermentation, protein analytics, and clinical research are expanding opportunities to develop food-derived peptides that support healthy aging, metabolic wellness, muscle health, recovery, and cognitive function.

Ultimately, the peptide conversation extends beyond a single class of ingredients, instead encompassing prescription medicines, compounded therapies, experimental compounds, and scientifically validated nutritional ingredients, each with distinct intended uses, regulatory pathways, and quality expectations.

“The biggest opportunities,” Catlin suggested, “will come from identifying novel food or supplement-derived peptides, generating strong clinical evidence, and bringing those ingredients to market through appropriate regulatory pathways.”

“That’s where I see the future of supplement peptides,” he continued, “not in trying to replicate pharmaceutical products, but in developing safe, well-characterized ingredients backed by solid science.”

As excitement surrounding peptides continues, the dietary supplement industry’s challenge will be ensuring consumers understand that not all peptides, or peptide categories, are created equal.